- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03126578
Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam
This is a single center, non-randomized, open-label, fixed sequence study to investigate the effect of multiple oral dosing of LEO 32731 (up-titrated), on CYP3A activity in healthy male subjects using midazolam as a probe CYP3A substrate.
The study will be conducted in two seamless parts:
Part I - Maximal Tolerated Dose (MTD) Part II - Drug-Drug Interaction with midazolam
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Neu-Ulm, Germany, 89231
- Nuvisan GmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the study restrictions.
- Subjects will be males between 18 and 55 years of age, inclusive.
- Subjects will have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive.
- Subjects must be in good health, as determined by medical history, physical examination, vital signs assessment, 12-lead ECG, and clinical laboratory evaluations.
Subjects (including those who have had a vasectomy) must agree to use condoms with spermicide during each sexual intercourse or must agree to be abstinent starting at first drug administration until 3 month after the final dosing.
Also subjects must agree not to donate sperm in the same time period.
- Subjects' female partner of childbearing potential must use an additional acceptable method of contraception. Eligible methods are: hormonal contraceptives (oral, injected, implanted, transdermal), intrauterine devices or systems (e.g. hormonal and non-hormonal IUD), barrier methods (condom and diaphragm, condom and cervical cap, etc.) in combination with a spermicide.
Exclusion Criteria:
- Subjects who have received any prescribed systemic or topical medication within 14 days of the first dose administration unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise safety.
- Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of the first dose administration (excluding occasional use of paracetamol or ibuprofen, e.g. in case of pain).
- Subjects who have received any medications, including St John's Wort known to alter drug absorption or elimination processes (change the enzyme levels) within 30 days of the first dose administration of study drug.
- Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug with new chemical entity within the past 60 days, or a marketed drug compound within the past 30 days prior to the first dosing.
- Subjects who have donated any blood, plasma or platelets in 3 months prior to first dosing or who have made donations on more than 3 occasions within the 12 months preceding the first dose administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All subjects
Part I - Maximum Tolerated Dose: All subjects will receive oral doses of LEO 32731 up-titrated from 10 mg bid on Days 1-3, 20 mg bid on Days 4-6 and 40 mg bid on Days 7-12. Part II - Drug-Drug Interaction: All subjects will receive oral doses of LEO 32731 in dose schedule decided upon data from Part I. Subjects will receive a single oral dose of 2.5 mg midazolam on Day -1 prior to the first dose of LEO 32731 and on Days 4, 7 and 17 of multiple dosing with LEO 32731. |
Benzodiazepine
LEO 32731 is being developed by LEO Pharma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) parameters of midazolam AUC0-t
Time Frame: Day -1 and Day 17
|
PK parameters AUC0-t will be analyzed on Day -1 and Day 17.
|
Day -1 and Day 17
|
Pharmacokinetic (PK) parameters of midazolam Cmax
Time Frame: Day -1 and Day 17
|
PK parameter Cmax will be analyzed on Day -1 and Day 17.
|
Day -1 and Day 17
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-t midazolam
Time Frame: Day 4 and Day 7
|
PK parameters of midazolam on Day 4 and Day 7 will only be calculated if relevant differences are seen in midazolam PK parameters between Day -1 and Day 17.
|
Day 4 and Day 7
|
AUC0-inf of midazolam
Time Frame: Day 4 and Day 7
|
PK parameters of midazolam on Day 4 and Day 7 will only be calculated if relevant differences are seen in midazolam PK parameters between Day -1 and Day 17.
|
Day 4 and Day 7
|
Cmax of midazolam
Time Frame: Day 4 and Day 7
|
PK parameters of midazolam on Day 4 and Day 7 will only be calculated if relevant differences are seen in midazolam PK parameters between Day -1 and Day 17.
|
Day 4 and Day 7
|
AUC0-inf of midazolam
Time Frame: Day -1 and Day 17
|
Further PK parameters (AUC0-inf, tmax, t1/2, CL/F and Vz/F) of midazolam on Days -1 and 17 (if applicable these parameters will be calculated on Day 4 and Day 7, too).
|
Day -1 and Day 17
|
Tmax of midazolam
Time Frame: Day -1 and Day 17
|
Further PK parameters (AUC0-inf, tmax, t1/2, CL/F and Vz/F) of midazolam on Days -1 and 17 (if applicable these parameters will be calculated on Day 4 and Day 7, too).
|
Day -1 and Day 17
|
t1/2 of midazolam
Time Frame: Day -1 and Day 17
|
Further PK parameters (AUC0-inf, tmax, t1/2, CL/F and Vz/F) of midazolam on Days -1 and 17 (if applicable these parameters will be calculated on Day 4 and Day 7, too).
|
Day -1 and Day 17
|
CL/F of midazolam
Time Frame: Day -1 and Day 17
|
Further PK parameters (AUC0-inf, tmax, t1/2, CL/F and Vz/F) of midazolam on Days -1 and 17 (if applicable these parameters will be calculated on Day 4 and Day 7, too).
|
Day -1 and Day 17
|
Vz/F of midazolam
Time Frame: Day -1 and Day 17
|
Further PK parameters (AUC0-inf, tmax, t1/2, CL/F and Vz/F) of midazolam on Days -1 and 17 (if applicable these parameters will be calculated on Day 4 and Day 7, too).
|
Day -1 and Day 17
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- LP0058-1324
- 2016-003882-24 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Interaction Potentiation
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
National Taiwan University HospitalCompletedDrug Interaction PotentiationTaiwan
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
SK Chemicals Co., Ltd.CompletedDrug Interaction Potentiation
-
Tianjin Medical University General HospitalCompleted
-
Il-Yang Pharm. Co., Ltd.CompletedDrug Interaction PotentiationKorea, Republic of
-
F-star Therapeutics, Inc.PRA Health SciencesCompletedDrug Interaction PotentiationNetherlands
-
Akebia TherapeuticsCompletedDrug Interaction PotentiationCanada
-
Il-Yang Pharm. Co., Ltd.Severance HospitalCompletedDrug Interaction PotentiationKorea, Republic of
Clinical Trials on Midazolam
-
PfizerCompleted
-
Seattle Children's HospitalCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedGout and HyperuricemiaChina
-
Nourhan M.AlyAlexandria UniversityCompleted
-
Korea University Anam HospitalCompletedChild | Anesthesia Morbidity | Delirium on EmergenceKorea, Republic of
-
Hamad Medical CorporationCompleted
-
Ain Shams UniversityCompleted
-
Nourhan M.AlyCompleted
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruiting
-
University Hospital, Basel, SwitzerlandCompletedCytochrome P450 CYP3A Enzyme DeficiencySwitzerland